Atomoxetine enhances connectivity of prefrontal networks in Parkinson's disease

Robin J. Borchert, Timothy Rittman, Luca Passamont, Zheng Ye, Saber Sami, Simon P. Jones, Cristina Nombela, Patricia Vázquez Rodríguez, Deniz Vatansever, Charlotte L. Rae, Laura E. Hughes, Trevor W. Robbins, James B. Rowe

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)
25 Downloads (Pure)

Abstract

Cognitive impairment is common in Parkinson’s disease (PD), but often not improved by dopaminergic treatment. New treatment strategies targeting other neurotransmitter deficits are therefore of growing interest. Imaging the brain at rest (‘task-free’) provides the opportunity to examine the impact of a candidate drug on many of the brain networks that underpin cognition, while minimizing task-related performance confounds. We test this approach using atomoxetine, a selective noradrenaline reuptake inhibitor that modulates the prefrontal cortical activity and can facilitate some executive functions and response inhibition. Thirty-three patients with idiopathic PD underwent task-free fMRI. Patients were scanned twice in a double-blind, placebo-controlled crossover design, following either placebo or 40-mg oral atomoxetine. Seventy-six controls were scanned once without medication to provide normative data. Seed-based correlation analyses were used to measure changes in functional connectivity, with the right inferior frontal gyrus (IFG) a critical region for executive function. Patients on placebo had reduced connectivity relative to controls from right IFG to dorsal anterior cingulate cortex and to left IFG and dorsolateral prefrontal cortex. Atomoxetine increased connectivity from the right IFG to the dorsal anterior cingulate. In addition, the atomoxetine-induced change in connectivity from right IFG to dorsolateral prefrontal cortex was proportional to the change in verbal fluency, a simple index of executive function. The results support the hypothesis that atomoxetine may restore prefrontal networks related to executive functions. We suggest that task-free imaging can support translational pharmacological studies of new drug therapies and provide evidence for engagement of the relevant neurocognitive systems.
Original languageEnglish
Pages (from-to)2171-2177
Number of pages7
JournalNeuropsychopharmacology
Volume41
DOIs
Publication statusPublished - 3 Feb 2016

Cite this